Company intelligence / Profile preview
BioSenic
Mont-Saint Guibert, Belgiumbiosenic.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioSenic has demonstrated positive Phase II results with its arsenic trioxide plus prednisone combination in cGVHD, showing a 75% overall response rate at 6 months. The ALLOB allogeneic cell therapy is in Phase II for orthopedic indications, while PREOB autologous cell therapy is in Phase III for osteonecrosis and non-union fractures. A pivotal Phase III trial of oral arsenic trioxide ("OATO"/"ArsciCor") as first-line treatment for cGVHD is being prepared following a positive FDA PreIND meeting
- Therapeutic areas
- NeurologyImmunologyRheumatologyOther
- Modalities
- Small molecule (arsenic trioxide)Cell therapyAllogeneic cell therapyAutologous cell therapyRecombinant protein (for bone regeneration products)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on BioSenic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioSenic.